Research To Practice | Oncology Videos

Featuring an interview with Dr Seth Wander, including the following topics: Design of SERENA-6, a Phase III switching trial of camizestrant for ESR1-mutant breast cancer during first-line treatment Turner N et al. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. Future Oncol 2023;19(8):559-73. Abstract (0:00) EMERALD trial analysis of patient-reported outcomes with oral elacestrant compared to standard of care endocrine therapy for ER-positive, HER2-negative advanced or metastatic breast cancer Cortes J et al. EMERALD trial analysis of patient-reported outcomes (PROs) in patients with ER+/HER2− advanced or metastatic breast cancer (mBC) comparing oral elacestrant vs standard of care (SoC) endocrine therapy. ESMO Breast 2023;Abstract 188O. (5:50) Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2-directed therapy, with or without abemaciclib, for ER-positive, HER2-positive advanced breast cancer Bhave MA et al. Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study. ASCO 2024;Abstract 1027. (9:43) CME information and select publications

Featuring perspectives from Dr Harry Paul Erba, moderated by Dr Stephen "Fred" Divers CME information and select publications

Featuring perspectives from Dr Edward B Garon, moderated by Dr Stephen "Fred" Divers CME information and select publications

Featuring perspectives from Dr Heather Wakelee, including the following topics: Introduction (0:00) Cases: A man in his late 50s with metastatic carcinoma of the lung, no actionable genomic alteration (AGA), PD-L1-negative, and a man in his early 60s with metastatic squamous cell carcinoma of the lung, PD-L1-negative — Brian P Mulherin, MD and Taral Patel, MD (8:08) Case: A man in his late 60s presenting with metastatic adenocarcinoma of the lung, multiple bone metastases, no AGA; PD-L1 20%; enrolled on ECOG-EA5163 — Priya Rudolph, MD, PhD (21:45) Current and Emerging Immunotherapeutic Strategies for Metastatic Non-Small Cell Lung Cancer (mNSCLC) (30:55) Case: An African American man in his early 60s with 6.2-cm squamous cell carcinoma of right upper lung receives neoadjuvant treatment as per CheckMate 816 — Dr Rudolph (39:16) Case: A man in his late 60s with pT2aN0 invasive adenocarcinoma of the right lower lung, no AGA; PD-L1 5% — Zanetta S Lamar, MD (44:57) Antibody-Drug Conjugates and Other Management Approaches for mNSCLC without AGAs (48:51) Case: A woman in her early 60s diagnosed in 2014 with metastatic adenocarcinoma of the lung treated on ECOG 5508 (carboplatin/paclitaxel/bevacizumab) receives nivolumab on disease progression — Dr Rudolph (56:35) CME information and select publications

Featuring perspectives from Dr Priyanka Sharma and Dr Sara M Tolaney, including the following topics: Introduction: Metastatic Triple-Negative Breast Cancer (mTNBC) — The Patient Perspective (0:00) Selection and Sequencing of Antibody-Drug Conjugates (5:09) Dosing and Tolerability of Sacituzumab Govitecan; Use of Anthracyclines (14:39) Case: A woman in her early 60s with relapsed TNBC (HER2 2+) who experiences disease progression on T-DXd (Grade 2 interstitial lung disease) and receives sacituzumab govitecan — Shaachi Gupta, MD, MPH (22:04) Discussing Palliative and End-of-Life Care (32:40) PARP Inhibitors for TNBC with Somatic versus Germline Mutations; Cytopenias with PARP Inhibitors (37:53) The "Art of Oncology" — Building Trust with Patients and Family Members (45:05) Case: A woman in her mid 60s with recurrent TNBC with extensive chest wall involvement — Dr Gupta (48:44) Case: A man in his mid 40s with multiregimen-refractory AR-positive TNBC with an ERBB2 exon 20 insertion mutation — Dr Gupta (52:53) CME information and select publications

Featuring perspectives from Dr Gloria Gerber, Dr Jamie Koprivnikar, Prof Alexander Röth and Dr Jamile M Shammo, including the following topics: Introduction: Paroxysmal Nocturnal Hemoglobinuria (PNH) and the General Medical Oncologist Diagnosis of and myths and misperceptions about PNH (0:00) Overview — Biology and Pathophysiology Role of complement activation in PNH; classification and clinical presentation (7:00) PNH treatments and their complement targets (21:37) Current Management Approaches Mechanistic similarities and differences between crovalimab and other available C5 inhibitors; potential practical advantages of crovalimab (24:56) Timing for initiation of treatment for PNH (32:08) Management of clinically significant extravascular hemolysis and residual anemia in patients with PNH receiving C5 inhibitor therapy (43:08) Risk of evolution to aplastic anemia or myeloid malignancy (45:54) Clinical trial database establishing the efficacy and safety of the C5 complement inhibitors eculizumab and ravulizumab for PNH (48:47) Activity and safety of and clinical experience with crovalimab (53:03) Monitoring and management of PNH in pregnant patients (58:37) Case Presentations Case: A woman in her early 30s who receives a new diagnosis of classical PNH with symptomatic anemia — Dr Gerber (1:03:44) Case: A man in his early 30s with PNH initially treated with eculizumab who is transitioned to ravulizumab — Dr Koprivnikar (1:17:32) Case: A woman in her early 50s with a remote history of aplastic anemia — Dr Gerber (1:32:24) Case: A woman in her late 20s with PNH receiving active C5 inhibitor therapy who wishes to discuss alternative treatment options — Dr Koprivnikar (1:38:00) CME information and select publications

Practical Perspectives: Investigators Discuss the Current Management of Paroxysmal Nocturnal Hemoglobinuria — Jamile M Shammo, MD CME information and select publications

Featuring an interview with Dr Seth Wander, including the following topics: ASCO Guidelines Rapid Recommendations Update for Testing for ESR1 Mutations (0:00) Real-world elacestrant use patterns and genomic biomarkers (4:43) Circulating tumor DNA (ctDNA) analyses with imlunestrant in the EMBER Phase I study (8:50) CME information and select publications

Featuring perspectives from Dr Sarah B Goldberg, Dr Brad S Kahl, Dr Sagar Lonial, Dr Joyce O'Shaughnessy, Dr Noopur Raje, Dr Joshua K Sabari, Dr Matthew R Smith, Dr Sonali M Smith, Dr Sandy Srinivas and Dr Seth Wander, including the following topics: Introduction (0:00) Current Therapeutic Approaches for Multiple Myeloma — Dr Lonial (0:37) Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates — Dr Raje (22:53) CME information and select publications

Featuring perspectives from Dr Suresh S Ramalingam and Dr Gregory J Riely, including the following topics: Introduction: Tumor Treating Fields (0:00) Nontargeted Therapy for Lung Cancer — Dr Ramalingam (4:02) Targeted Therapy for Non-Small Cell Lung Cancer — Dr Riely (33:50) CME information and select publications